Novo Nordisk registers Phase 3 trial of CagriSema in hypertension and obesity
The study, titled Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity, plans to enroll 1408 participants and is expected to start on November 11, 2026. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo in a randomized, quadruple-masked design.
Primary source
ClinicalTrials.gov registry record, November 5, 2026
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
Read the source: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation